2 Feb 2017 07:00
2 February 2017
C4X Discovery Holdings plc
("C4XD" or the "Company")
GRANT OF OPTIONS AND DIRECTORS DEALING
C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, announces that on 1 February 2017, 100,000 options over ordinary shares of the Company ("Ordinary Shares") were awarded pursuant to the EMI 2014 Plan to certain employees, including 50,000 options to Dr. Craig Fox, Chief Scientific Officer, as set out below.
Name | Position | Number of share options awarded | Option exercise price per share (pence) | Percentage of issued share capital (%) |
Craig Fox | Chief Scientific Officer | 50,000 | 91 | 0.13% |
Following this award, Craig Fox holds options over 200,000 Ordinary Shares, representing 0.53% of the Company's issued share capital. The options have an exercise price of 91p, being the average of the mid-market closing price of the Ordinary Shares over the three days prior to 1 February 2017. The options can be exercised at any time between 3 years and 10 years of them being granted.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name
| Dr. Craig Fox | ||||
2 | Reason for the notification | |||||
a) | Position/status
| Chief Scientific Officer, Director | ||||
b) | Initial notification/Amendment
| Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | C4X Discovery Holdings plc | ||||
b) | LEI | 213800UHNL82E323O870 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | options over 1p ordinary shares - EMI 2014 Plan
ISIN GB00BQQ2RV18 | ||||
b) | Nature of the transaction
| Grant of options over ordinary shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information
|
| ||||
e) | Date of the transaction
| 1 February 2017 | ||||
f) | Place of the transaction
| N/A | ||||
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Zeus Capital Limited
Dan Bate 0161 831 1512
Dominic Wilson/Phil Walker 0203 829 5000
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Melissa Gardiner 0203 709 5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4X's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in addiction, diabetes and inflammation with a number of new drug candidates identified and further progress made towards the clinic. In selecting new targets C4X Discovery will focus on the high-value disease areas of inflammation and neurodegeneration, and will continue to maximise value from opportunistic areas, for example, immuno-oncology.
The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4X to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com